Navigation Links
Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting

ormation, please visit our website (www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward- looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 15, 2007 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

     Contact:

     Denise T. Powell

     Sr. Director, Corporate Communications

     Threshold Pharmaceuticals, Inc.

     650-474-8206
dpowell@thresholdpharm.com

CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, dpowell@thresholdpharm.com

Web site:




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/19/2009)...9 The D e al magazin...st Admired Corporate Dealmakers for the second con...ost Admired Dealmaker in pharma/biotech for the mo...estitures since January 2006. ,, Over the past ... with a focus on high-growth, innovation-driven bu...
(Date:11/19/2009)...Internet Week of Action ,, SILVER SPRING, Md.,...and Drug Administration today completed a coordina...ternational Internet Week of Action (IIWA), intend...cts. ,, (Logo: http://www.newscom.com/cgi-bin/...he FDA,s Office of Criminal Investigations (OCI), ...
(Date:11/19/2009)... Impliant, Inc., a developer of no...nal fusion surgery, announced today that it has ad... the Vice President of Clinical and Regulatory Aff...-bin/prnh/20080527/NETU060LOGO ) ,, Mr. Rolon...ence in the spinal and medical device field to Imp...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3The Neutraceutical Company Announces Powerful New Feel Good Product 52215 1The Neutraceutical Company Announces Powerful New Feel Good Product 52215 2Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 1Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 2Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 52211 3The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 1The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 2The Secrets to Staying Beautiful 3B Making the Most of Your Beauty Budget 52206 3
...g-Plough,Corporation (NYSE: SGP ) today reported ...ine, a fast-dissolving, sublingual tablet being,de...ffective than placebo,and well tolerated in treati...to the results, asenapine 5 mg twice daily and 10 ...ive than placebo at improving,patient Positive and...
... into Treatment Impact, Node-Positive ...D CITY, Calif., Dec. 17 Genomic Health,Inc. (Nasd...studies,reinforcing the clinical utility of the co...st to predict the likelihood of recurrence and the...rtion of early-stage,breast cancer patients. This ...
Other Medicine Technology:New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 2Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 3Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 5Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 6Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 7
(Date:11/20/2009)...as 34 weeks, potentially adding to preemie deliver...(HealthDay News) -- Recent reports show that the r...e United States. Now, a new study suggests one re...itutes a full-term birth in the first place. , ...tudy considered a baby born at 34 to 36 weeks of g...
(Date:11/20/2009)...gh and is expected to continue, CDC says, , ...eas of the United States are seeing declines in H1...aid Friday, and while the disease remains widespre...ported last week. , "We are beginning to see so...ry, but there is still a lot of influenza everywhe...
(Date:11/20/2009)... Nov. 20 Missouri state employees ...s will now have the option to choose Mercy Health ...en Missouri Consolidated Health Care Plan (MCHCP) ...uth Central Missouri regions include the following...Dallas, Douglas, Greene, Hickory, Howell, Jasper, ...
(Date:11/20/2009)... Nov. 20 The Louisi...d that Louisianians could experience higher health...eing considered by Congress should become law. ,... for LAHP, "Louisiana health plans have supported ...ng of the national debate. Our plans have offered...
(Date:11/20/2009)...ov. 20 The US governmen...ggled to get enough food to eat. This startling s...ts who are rapidly aging into poverty. "Forced re...ivorce mean many have incomes that no longer cover... Older women are particularly vulnerable," said K...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...respiratory disease can walk further, and are less...e. Exercise is key to pulmonary// rehabilitation i...is to increase the distance they can walk in a fix...l effect of music when walking for such patients. ...
...ood coping style helps women to deal positively wi...r mental attitude makes a difference in the fight ...oking// at several studies and they conclude that ...to 44 per cent of women experienced anxiety and de...
... background of the surgeon does not affect the out... Glasgow have surveyed 4,139 melanoma patients who... They found the outcomes to be similar, whether th... breast surgeons generally get better results than...
...tins reduce the risk of heart attack in older peop...terol// levels and so lowers the risk of heart dis...-aged people, but the benefits for the elderly hav... of 4,050 men and women aged between 75 and 80 yea...
...susceptibility to lead is still a public health co...d over the past two decades. Previous studies hav... potential// cause for cancer, kidney disease, car...o mortality in the general population. Resea...
...atients and thereby recuperates their energy level...chemotherapy. It results from a decrease in levels... round the body. The problem with anaemia is that ... tasks. A new treatment, epoetin alfa, mimic...
Other Medicine News:
The Poncho Apron
MSP-3 Special Procedure wrap-around with Integrated Wide Belt
MSWB-1 Strap Apron with Wide Belt
MSV-10 Adjustable Velcro
Medicine Products: